Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 36

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 36
---
 of the Kineta Merger have been satisfied (other than conditions that cannot be satisfied until on or immediately before the closing of the Kineta Merger) and that the Company is prepared to close the Kineta Merger (the
“Fourth Closing Date”).

3. . Except as set forth in the SEC Reports,
the Company hereby represents and warrants to each of the Investors and the Placement Agents that the statements contained in this are true and correct as of the date of this Agreement and as of the Applicable
Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date).

3.1
. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada, has the requisite power and authority to own, lease and operate its properties and to carry on
its business as now conducted and described in the SEC Reports and is qualified to do business in each jurisdiction in which the character of its properties or the nature of its business requires such qualification, except where such failure to be
in good standing or to have such power and authority or to so qualify would not reasonably be expected to have a Material Adverse Effect. Each of the Company’s subsidiaries is (i) duly incorporated and validly existing and in good standing
under the laws of the jurisdiction of its incorporation and has the requisite power and authority to carry on its business as now conducted and to own or lease its properties and (ii) qualified to do business as a foreign corporation and in
good standing in each jurisdiction in which such qualification is required, except in each case as would not reasonably be expected to cause a Material Adverse Effect.

3.2 . The Company’s disclosure of its authorized, issued and outstanding capital stock in the SEC Reports containing
such disclosure was accurate in all material respects as of the date indicated in such SEC Reports. All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company which have not been waived, and
such shares were issued in compliance in all material respects with applicable state and federal securities law and any rights of third parties. The Purchasers understand that the issuance of the shares of Common Stock underlying the Warrants is
subject to the approval of the Authorized Share Increase Proposal (as defined in the Company